Arshad Khanani, MD
Show Description +
Arshad Khanani, MD, shares results of the phase 2 STAIRWAY study, a randomized study comparing extended 16-week and 12-week dosing of faricimab (formerly RG7716, Genentech) in patients with neovascular age-related macular degeneration with ranibizumab dosed every 4 weeks.
Posted: 10/28/2018
Arshad Khanani, MD
Arshad Khanani, MD, shares results of the phase 2 STAIRWAY study, a randomized study comparing extended 16-week and 12-week dosing of faricimab (formerly RG7716, Genentech) in patients with neovascular age-related macular degeneration with ranibizumab dosed every 4 weeks.
Posted: 10/28/2018
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of AAO: 2018.
Please log in to leave a comment.